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Available online 31 March 2016Introduction: The Safety Pharmacology Society (SPS) and National Centre for the Replacement, Reﬁnement & Re-
duction of Animals in Research (NC3Rs) conducted a survey and workshop in 2015 to deﬁne current industry
practices relating to housing of non-rodents during telemetry recordings in safety pharmacology and toxicology
studies. The aim was to share experiences, canvas opinion on the study procedures/designs that could be used
and explore the barriers to social housing.
Methods: Thirty-nine sites, either running studies (Sponsors or Contract Research Organisations, CROs) and/or
outsourcing work responded to the survey (51% from Europe; 41% from USA).
Results: During safety pharmacology studies, 84, 67 and 100% of respondents socially house dogs, minipigs and
non-human primates (NHPs) respectively on non-recording days. However, on recording days 20, 20 and 33%
of respondents socially house the animals, respectively. The main barriers for social housing were limitations
in the recording equipment used, study design and animal temperament/activity. During toxicology studies,
94, 100 and 100% of respondents socially house dogs, minipigs and NHPs respectively on non-recording days.
However, on recording days 31, 25 and 50% of respondents socially house the animals, respectively. The main
barriers for social housing were risk of damage to and limitations in the recording equipment used, food con-
sumption recording and temperament/activity of the animals.
Conclusions: Although the majority of the industry does not yet socially house animals during telemetry record-
ings in safety pharmacology and toxicology studies, there is support to implement this reﬁnement. Continued
discussions, sharing of best practice and data from companies already socially housing, combined withKeywords:
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76 H. Prior et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 75–87technology improvements and investments in infrastructure are required tomaintain the forwardmomentumof
this reﬁnement across the industry.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The assessment of cardiovascular function (electrocardiogram
(ECG), heart rate and blood pressure) within a non-rodent species is a
regulatory requirement for all new chemical entities (NCEs) prior to
ﬁrst administration in man (ICH, 2001 S7A; ICH, 2005 S7B). This is usu-
ally performed as a safety pharmacology telemetry study (Leishman,
Beck, Dybdal, Gallacher, Guth, Holbrook, Roche, & Wallis, 2012) in spe-
cies such as the dog (Chaves, Zingaro, Yordy, Bustard, O'Sullivan,
Galijatovic-Idrizbegovic, Schuck, Christian, Hoe, & Briscoe, 2007;
Gauvin, Tilley, Smith, & Baird, 2006), Göttingen minipig (Authier,
Gervais, Fournier, Gauvin, Maghezzi, & Troncy, 2011; Markert,
Stubhan, Mayer, Trautmann, Klumpp, Schuler-Metz, Schumacher, &
Guth, 2009) or cynomolgus macaque (Authier, Tanguay, Gauvin, Di
Fruscia, Fournier, Chaurand, & Troncy, 2007; Chaves, Keller, O'Sullivan,
Williams, Fitzgerald, McPherson, Goykhman, Ward, Hoe, Mixson, &
Briscoe, 2006).With the development of non-invasive jacketed teleme-
try for dogs (Chui, Fosdick, Conner, Jiang, Bruenner, & Vargas, 2009;
Prior, McMahon, Schoﬁeld, & Valentin, 2009; Ward, Milliken, Patel, &
McMahon, 2012; Kremer, Bills, Hanke, Chen, Meier, Osinski, & Foley,
2015), minipigs (Ascah, Abtout, Pouliet, Bassett, & Authier, 2015;
Diehl, Nungester, & Regalia, 2015) and cynomolgus monkeys
(McMahon, Mitchell, Klein, Jenkins, & Sarazan, 2010; Derakhchan,
Chui, Stevens, Gu, & Vargas, 2014), cardiovascular endpoints may be in-
tegrated into toxicology studies (Authier, Vargas, Curtis, Holbrook, &
Pugsley, 2013; Redfern, Ewart, Lainée, Pinches, Robinson, & Valentin,
2013; ICH, 2009a M3(R2)), providing valuable data following repeat-
dosing. For biopharmaceuticals or anti-cancer agents the toxicology
studies may be the only source of cardiovascular data, as a stand-alone
safety pharmacology study is not always required (ICH, 2011 S6(R1);
ICH, 2009b S9; Vargas, Bass, Breidenbach, Feldman, Gintant, Harmer,
Heath, Hoffmann, Lagrutta, Leishman, McMahon, Mittelstadt,
Polonchuk, Pugsley, Salata, & Valentin, 2008).
Housing practices that support good welfare are a top priority in de-
signing a scientiﬁcally sound study to obtain high quality cardiovascular
data. To generatemore representative baselinephysiology, avoid abnor-
mal behaviour and for psychological wellbeing, social species, including
many commonly used laboratorymammals, should be housed in stable,
compatible pairs or groups (social housing). Dogs, minipigs and NHPs
exist in groups in nature and social interaction is known to be required
for psychological well-being (Prescott, Morton, Anderson, Buckwell,
Heath, Hubrecht, Jennings, Robb, Ruane, Swallow, & Thompson, 2004;
Ellegaard, Cunningham, Edwards, Grand, Nevalainen, Prescott, &
Schuurman, 2010; Jennings & Prescott, 2009). When housed in social
groups within the laboratory environment, these animals are able to
copemore effectively with potential stressors, exhibit less stereotypical
behaviour and have a more balanced temperament (see DiVincenti &
Wyatt, 2001 for a review). Additionally, pair-housed dogs have been
shown to have lower heart rates and fewer vocalisations (Klumpp,
Trautmann, Markert, & Guth, 2006), or fewer stereotypic behaviours
(Hetts, Clark, Calpin, Arnold, & Mateo, 1992) than dogs housed alone,
whilst isolated pigs show a chronic stress response when compared to
group housed pigs (Kanitz, Tuchscherer, Puppe, Tuchscherer, &
Stabenow, 2004; Ruis, te Brake, Engel, Buist, Blokhuis, & Koolhaas,
2001a). Accordingly, the regulations and policies surrounding housing
of non-rodents specially mention the requirement for social housing
(e.g., Directive 2010/63/EU, 2010; NC3Rs, 2006; Institute for
Laboratory Animal Research, 2011). These are often supplemented by
non-governmental systems of oversight, such as voluntary participationby institutions in accreditation programmes (e.g., AAALAC internation-
al), company global animal welfare processes (e.g., AWERB/IACUC),
and the peer review processes and grant terms and conditions of re-
search funding bodies (e.g., ARRIVE guidelines; Kilkenny, Browne,
Cuthill, Emerson, & Altman, 2010; McGrath, Drummond, McLachlan,
Kilkenny, & Wainwright, 2010). The most current updates to interna-
tional animal welfare regulations speciﬁcally state ‘except those which
are naturally solitary, shall be socially housed in stable groups of com-
patible individuals' (Directive 2010/63/EU, 2010) and ‘single housing
of social species should be the exception’ (Institute for Laboratory
Animal Research, 2011).
Although it is a general practice to socially house non-rodents on
safety pharmacology and toxicology studies on non-telemetry record-
ing days, the majority of the pharmaceutical industry will separate ani-
mals for data collection on the speciﬁc telemetry recording days within
a study (Ewart, Milne, Adkins, Benjamin, Bialecki, Chen, Ericsson,
Gardner, Grant, Lengel, Lindgren, Lowing, Marks, Moors, Oldman,
Pietras, Prior, Punton, Redfern, Salmond, Skinner, Some, Stanton,
Swedberg, Finch, & Valentin, 2013; McMahon, Mitchell, Klein, Jenkins,
& Sarazan, 2010;Ward,Milliken, Patel, &McMahon, 2012). This separa-
tion of animals is considered by some to be justiﬁed to allow conduct of
the speciﬁc scientiﬁc procedure (telemetry recording), such that the
overall objectives of the experiment can be achieved. Although animals
are usually acclimatised to these instances of periodic isolation, this can
contribute to increases in heart rate (Xing, Lu, Hu, Wang, Zhao, Zheng,
Schoﬁeld, Oldman, Adkins, Yu, Platz, Ren, & Skinner, 2015) which may
impact study data. However, with the goal of social housing as default,
the industry has come together to investigate ways to move towards
these preferred conditions. Integration of cardiovascular recordings
into repeat-dose toxicology studies, and/or the requirement for longer
duration or more frequent recording periods within a study (e.g., for
compounds with long pharmacokinetic half-lives, or for biologicals
with unique mechanisms of action), may lead to increasing amounts
of isolation time compared to ‘standard’ safety pharmacology studies.
This further emphasises the importance of reﬁnement of housing prac-
tices during telemetry recordings.
Historically, single housing of animals has partly been a consequence
of limitations in the equipment used (e.g. spatial separation of animals
was required to avoid cross-talk between signals transmitting on the
same frequency). However, some systems have been available that
allowed and supported recording from multiple animals within the
same area due to transmissions on multiple frequencies (Klumpp,
Trautmann, Markert, & Guth, 2006; Markert, Trautmann, Groß, Ege,
Mayer, &Guth, 2012;Ward, 2009) but it has not been a standard feature
across telemetry manufacturers. Recent technological advances now
offer multiple frequencies to be transmitted and recorded as standard,
thus increasing the feasibility of wider adoption of recordings from so-
cially housed animals (Bétat, Coquelin, Infanti, Delpy, & Drieu la
Rochelle, 2014; Kearney, Appleby, Kieper, & Atterson, 2016 (this
issue); Milano, Bory, Dupuis, Chalencon, Lege, Fant, Webb, & Singer,
2013; Niehoff, Sternberg, Niggemann, Sarazan, & Holbrook, 2014;
Tichenor, Regalia, Holzgrefe, Lilly, Wilcox, & Kaiser, 2016 (this issue)).
Although this technological advancewould address one of themajor
barriers to implementation of social housing during telemetry record-
ings, many companies still require additional information before
investing in new equipment and infrastructure. One key barrier to
change is that the validation of telemetry data acquisitions systems
and generation of subsequent historical data sets have been mainly
from single housed animals. There is also a perception that recordings
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distinct from) single-housed animals due to increased interactionswith
pen/cagemates, leading to a decreased sensitivity (statistical power) to
detect changes in cardiovascular parameters. Nevertheless, some com-
panies have started to validate processes and approaches for running
safety pharmacology and toxicology studies using animals grouped to-
gether in pairs, threes or fours for the duration of the study (Kaiser,
Tichenor, Regalia, York, & Holzgrefe, 2015; Prior, Billing, Wallace,
South, Oldman, Moors, Edmunds, & Milne, 2015; Xing, Lu, Hu, Wang,
Zhao, Zheng, Schoﬁeld, Oldman, Adkins, Yu, Platz, Ren, & Skinner,
2015), in addition to those companies for whom this has been the stan-
dard for many years (Klumpp, Trautmann, Markert, & Guth, 2006).
In 2015 the SPS (http://www.safetypharmacology.org) and the
NC3Rs (http://www.nc3rs.org.uk) established a working group to col-
lect information on current housing practices of non-rodents during
the collection of cardiovascular telemetry data on both safety pharma-
cology and toxicology studies. Further objectives were to share experi-
ences and canvas opinion on the study procedures/designs that could
be used for socially housing animals during telemetry recording periods
andwhat barriers exist preventing this. Theworking group is facilitated
by the NC3Rs and currently represents seven global pharmaceutical
companies and six CROs (see author afﬁliations). The working
group contains some companies with experience of successfully
implementing social housing to others with no experience of this. The
data within this manuscript represent the outcome of an international
industry survey conducted in the summer of 2015 and a workshop at
the SPS Annual Meeting in October 2015.
2. Methods
The questionnaires were sent to targeted individuals within the
safety pharmacology and toxicology communities worldwide, with re-
sponsibility for either running studies in-house or for outsourcing this
work. Different questionnaires were sent to CROs and Sponsors, to
allow for the capture of information fromgroupswho run studies them-
selves (categorised as CRO or Sponsor in-house) and those that out-
source studies (Sponsor outsource).
2.1. Survey questions
Questions were asked around the themes below, for safety pharma-
cology and toxicology studies separately, and with separate responses
for dog, minipig and NHP (speciﬁed as the cynomolgus macaque) as
appropriate:
(1) How do you house non-rodents on telemetry recording and non-
recording days?
(2) What are the barriers preventing the social housing of non-
rodents on recording days? (respondents were requested to
choose multiple reasons from a list and then indicate the major
reason)
(3) What are the barriers preventing the utilisation of a companion
animal on recording days in safety pharmacology studies?
(4) Do you have any positive or negative experiences with social
housing during recording sessions?
(5) Is there an impact on the data quality if the animals are socially
housed during telemetry recording?
(6) How many animals, and which sex, do you use for safety phar-
macology telemetry studies?
Comment boxes were provided throughout the survey to allow sub-
mission of additional information and expression of any concerns. Def-
initions were clariﬁed within the survey as follows:
(1) Social housing: an animal is housed with at least one pen/cage
mate for 24 h a day (apart from veterinary reasons for single
housing);(2) Partial social housing: an animal is housed with at least one pen/
cage mate for the majority of the day, apart from during study
procedures (e.g., separation for recording of food consumption
or clinical sign observations immediately post-dose);
(3) Individual housing: an animal is housed alone in the pen/cage
(note, the animal may or may not have contact with other ani-
mals through the bars or adjoining pens/cages).
(4) Companion animal: an additional animal is housed in the same
pen/cage as the recorded animal. This animal may be part of
the study (e.g., dosed and recorded on a different day) or may
be an undosed animal (e.g., part of the stock colony) provided
solely for companionship.
Respondents were requested to provide answers focussed on the
most representative/most frequently run cardiovascular telemetry
study designs at their facility. Therefore, the responses may relate to
early (non-GLP) investigative studies and/or ‘regulatory’ GLP studies
intended for regulatory submission. Respondents were requested to
provide answers for routine regulatory toxicology studies.
3. Results
Multiple replies were received from some companies, reﬂecting the
presence of these companies at different sites worldwide. As these sites
may have different standard practices, they were included in the analy-
sis as separate replies. Where a Sponsor only outsourced studies, their
opinions regarding the barriers to the adoption of social housing were
included in the results.
Eighteen CRO and 21 Sponsor sites responded. 72% ran safety phar-
macology telemetry studies and 44% ran toxicology studies with cardio-
vascular telemetry recording in their facility in at least one of the
species. The number of replies across the different species and types of
studies are presented in Fig. 1a. A larger number of Sponsors conduct
safety pharmacology studies in-house when compared to toxicology
studies, which the majority of Sponsors appear to outsource. Replies
were received mainly from companies within USA (41%) or Europe
(51%), (Fig. 1b).
3.1. Safety pharmacology responses
3.1.1. How many animals are used on telemetry studies
The majority of respondents used four animals of a single sex for
safety pharmacology studies. However, there was some variation in
the number of animals used and evaluation of both sexes (Fig. 2), in-
creasing the number up to eight animals per study. There was little dif-
ference in the number of animals used according to species, with the
majority of respondents using the same number of animals regardless
of species (i.e., 4, 6 or 8).
3.1.2. Acclimatisation and housing on non-recording and recording days
Acclimatisation procedures vary widely across the respondents, ac-
cording to where in the facility animals are housed in relation to stock
colonies. 54% of responses indicated that animals are housed in the
same room as the recording pen/cages, but might move to another
penwithin the room for the recording period. Some animals are housed
in a different room outside of studies, butmove to recording pens/cages
in a dedicated room for studies. For these animals, acclimatisation times
to the recording pen/cage range from 0 to N12 days, however most re-
spondents (75%) acclimatise for 1–6 days. The majority of respondents
(79%) indicated that the animals then remain in the recording room
throughout the study rather than being moved back to a stock area be-
tween recording sessions.
The majority of respondents social house or partially-social house
their animals on non-recording days (84, 67 and 100% of respondents
for dogs, minipigs and NHPs respectively). However, this reduces on
Fig. 1. a: Survey respondents per study type and species. The number of respondents to the survey from Sponsors (running in-house studies and/or outsourcing studies) and CROs, for
safety pharmacology and toxicology studies in the different non-rodent species. The numbers within the bars gives the actual number of respondents, for ease of reading. b: Survey
respondents by geographical location. The overall number of respondents to the survey by geographical location. The numbers within the chart gives the actual number of
respondents, for ease of reading.
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Themajority (7/9) of respondents that house socially during the record-
ing period are fromEuropean countries and this practice is slightlymore
prevalent in studies using NHPs than dogs (5 vs 8).3.1.3. Barriers for social housing during safety pharmacology telemetry
studies
Reasons for not housing animals socially during recordings were
similar across species (Table 1, Safety Pharmacology Telemetry col-
umn). The top three major reasons were i) limitations of the recording
equipment, ii) study design requirements and iii) temperament/activity
of the animals. The majority of respondents listed four to six reasons
preventing social housing, indicating that although the limitations inrecording equipment is the major barrier, there are still many other
barriers.
3.1.4. Companion animal use
If the equipment does not allow recording of telemetric data from
multiple animals in the same area, one option to maintain social hous-
ing is to use a companion animal. Some respondents had experience
implementing this approach (7/25 for dog, 3/15 for minipig and 6/23
for NHP respondents).
Reasons for not housing animals with a companion were similar
across the species and included the risk of cross-contamination, sponsor
expectations, fate of the un-dosed animal, impact on costs/size of colony
and size of cages/number of available cages (Table 1, CompanionAnimal
Telemetry column). The majority of respondents listed one to three
Fig. 2.Number and sex of animals used on safety pharmacology telemetry studies. The number of respondents using between 4 and 8 animals, and a combination of single or both sexes, on
safety pharmacology telemetry studies. The numbers within the bars gives the actual number of respondents, for ease of reading.
79H. Prior et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 75–87reasons preventing social housingwith a companion, indicating that al-
though the risk of cross contamination to the un-dosed animal is the
major barrier, there are still other reasons and barriers to overcome.
3.1.5. Data quality responses
The majority of respondents with experience of social housing for
safety pharmacology studies indicated that the data quality was the
same or better than data obtained from individually housed animals
(9/10 for dog, 4/4 for minipig and 10/11 for NHP respondents, respec-
tively). Further expansion of these qualitative answers was not request-
ed within the survey.
3.1.6. Plans for changing to social housing
Overall, the industry is receptive to social housing during recordings
on safety pharmacology telemetry studies and some companies have
already implemented social housing (CROs: 3 dog, 2 minipig and 5
NHP respondents; Sponsors: 2 dog, 1 minipig and 3 NHP respondents).
Other companies are considering social housing in the future (Fig. 4);
however, a different pattern is evident between CROs and Sponsors run-
ning studies in-house. For CROs, 10/12 dog respondents, 6/7minipig re-
spondents and 9/11 NHP respondents who had not yet implemented
social housingwere actively planning to do so. Conversely for Sponsors,Fig. 3. Housing on recording and non-recording days (safety pharmacology studies). The num
recording days within a safety pharmacology telemetry study. The numbers within the bars gionly 1/5 dog respondents, 0/1 minipig respondents and 1/2 NHP re-
spondents who had not yet implemented social housing were actively
planning to implement this.
3.2. Toxicology responses
3.2.1. Methods currently used to measure cardiovascular data within toxi-
cology studies
There are a number of possible methods utilised for the recording of
cardiovascular data within regulatory toxicology studies:
(1) snapshot approach (use of external ECG electrodes and blood
pressure cuff attached for short periods of time at speciﬁc
timepoints and days within the study),
(2) use of a jacketed telemetry system (external ECG electrodes at-
tached, sometimes with blood pressure cuff or minimally-
invasive blood pressure implants in addition, covered with a
jacket holding the hardware for continuous telemetric transmis-
sion on speciﬁc days within a study), and
(3) implanted telemetry device (surgical implantation of telemetry
hardware for continuous telemetric transmission of ECG and
blood pressure waveforms on speciﬁc days within a study).ber of respondents housing their animals socially or individually, on recording or non-
ves the actual number of respondents, for ease of reading.
Table 1
Reasons stated for not social-housing in safety pharmacology and toxicology telemetry studies.
Safety pharmacology telemetrya Companion animal telemetryb Toxicology telemetry
Dog (29) Minipig (17) NHP (26) Dog (20) Minipig (11) NHP (19) Dog (22) Minipig (11) NHP (21)
Limitations of recording equipment currently being used 79 82 92 50 64 52
Study Design 66 76 62
Damage to equipment 5 0 0 64 55 48
Sponsor requirement/expectationc 57 (14) 42 (12) 46 (13) 67 (12) 71 (7) 75 (12) 63 (8) 20 (5) 50 (8)
Housing options available at CROc 60 (10) 50 (4) 36 (11)
Temperament of individual animals 52 47 50 41 45 38
Monitoring of clinical signs observed 45 24 31 41 27 38
Colony management 21 29 46
Food consumption recording of individual animals 38 29 27 59 55 48
Size of pen/cage/No. of pens/cages in the recording room 28 35 69 20 27 21 27 36 19
Increased/abnormal activity 34 24 31 32 27 33
Quality of data obtained 34 29 23 36 36 29
Validation of processes required 28 24 23 36 45 38
How the recording room is set-up 24 6 23 23 18 24
Size of animals 3 12 15 9 18 19
Cross-contamination 0 0 4 70 73 68
Fate of un-dosed animal 45 45 37
Impact on costs/increase in colony size 20 18 21
Risks of conﬂicts between animals 5 0 5
Availability/compatibility of companion animal 5 9 0
Data represented is % of respondents (the number in brackets next to species indicates the number of replies received for that species and subset of the survey).
a Where two or more animals have telemetry recordings simultaneously from within the same pen/cage.
b Where only one animal has telemetry recordings but an undosed animal is present within the same pen/cage. For the companion animals' answers, these were different/additional
options to the safety pharmacology telemetry answers.
c These questions were only asked of either the CRO or Sponsor and therefore the total number of respondents is different than the other replies and is stated in brackets next to the
percentage.
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thesemethodswithin their facilities (Table 2). However, the percentage
of studies performedwith jacketed telemetry technologywas low, with
most respondents (65%) indicating that only 1–40%of their studies used
jacketed telemetry (Table 3). For the remainder of the questions the
focus was only on studies using jacketed telemetry, as this method of
recordingmay impact the housing of the animals. [Snapshot ECG collec-
tions (the secondmost commonly used toxicology method) has no im-
pact to housing practices, as animals are removed to procedure rooms
for this. Implanted telemetry technology will encounter the same bar-
riers as the safety pharmacology recordings described previously.]
3.2.2. Acclimatisation to jackets
Unlike safety pharmacology studies, the majority of respondents in-
dicated that the animals remain in the same pen/cage for the recordingFig. 4. Plans for implementation to social housing during recordings (safety pharmacology stud
recordings in safety pharmacology telemetry studies. The numbers within the bars gives the asessions as for the rest of the toxicology study (e.g. animals are either in-
dividually housed throughout the study, or the pens for socially housed
animals are divided and animals are kept separate for recordings). The
majority (75%) of respondents acclimatise the animals to the jackets
prior to the ﬁrst recording occasion only. The number of acclimatisation
sessions ranged from 0 to 9, with themajority of respondents indicating
that they acclimatised for 1–3 occasions prior to the ﬁrst recording ses-
sion. There were no apparent differences in the number of acclimatisa-
tion sessions used for the different species.
3.2.3. Housing on non-recording and recording days
Themajority of respondents social or partially-social house their an-
imals on non-recording days (94, 100 and 100% of respondents for dogs,
minipigs and NHPs respectively). However, this reduces on recording
days to 31, 25 and 50% of respondents, respectively (Fig. 5).ies). The number of respondents planning to implement social housing of animals during
ctual number of respondents, for ease of reading.
Table 2
Methods currently available to measure cardiovascular parameters on toxicology studies.
Dog Minipig NHP
CRO (12) Sponsor (5) Total (17) CRO (7) Sponsor (1) Total (8) CRO (13) Sponsor (4) Total (17)
Snapshot 11 3 14 6 0 6 12 3 15
Jacketed telemetry 11 5 16 6 1 7 12 4 16
Implanted telemetry 7 2 9 3 0 3 9 1 10
Data presented is number of respondents. Respondents were able to choose multiple options, in brackets is the total number of responses received.
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there was a similar number of European (5) and non-European
(4) countries, however, similar to the safety pharmacology results this
practice was more prevalent in studies using NHPs than dogs.
3.2.4. Barriers for social housing during toxicology studies
Reasons for not housing animals socially during recordings were
similar across the species (Table 1, Toxicology Telemetry column). The
top fourmajor reasonswere i) potential damage to the recording equip-
ment, ii) technical limitations of the recording equipment, iii) food con-
sumption recording and iv) temperament/activity of the animals. The
majority of respondents had several reasons for not housing socially,
with some citing up to eight reasons, indicating that although the po-
tential damage to equipment is the major barrier, there are still many
other barriers.
3.2.5. Data quality responses
The majority of respondents with experience of social housing dur-
ing toxicology studies indicated that the data quality was the same or
better than from individually housed animals (8/9 for dog, 3/3 for
minipig and 8/9 for NHP respondents, respectively). Further expansion
of these qualitative answers was not requested within the survey.
3.2.6. Plans for changing to social housing
Although a lownumber of responseswere received for this question,
some companies are considering social housing during cardiovascular
recordings within toxicology studies in the future. For CROs, 2/4 dog re-
spondents, 1/1minipig respondents and 2/3 NHP respondents who had
not yet implemented social housingwere actively planning to do so. For
Sponsors, 1/3 dog respondents and 0/1 NHP respondents who had not
yet implemented social housing were actively planning to implement
this. A similar number of CROs and Sponsors have already implemented
social housing (CRO: 4 dog, 2 minipig and 5 NHP respondents; Sponsor:
1 dog, 0 minipig and 3 NHP respondents).
4. Discussion
The purpose of this survey and the subsequent workshopwas to de-
scribe current practices for housing non-rodents during cardiovascular
telemetry recordings in safety pharmacology and toxicology studies,
with the further goal of identifying opportunities for the expansion of
social housing across entire study durations. Although the majority of
respondents already house animals socially on non-recording days,
most revert to individual housing on days when cardiovascular data is
acquired. However, many respondents were in favour of implementing
social housing during recordings, with some companies alreadyTable 3
Percentage of toxicology studies using jacketed telemetry.
Dog Minipig NHP
CRO Sponsor Total CRO Sponsor Total CRO Sponsor Total
1–40% 7 2 9 3 0 3 8 2 10
41–80% 3 1 4 2 0 2 2 2 4
81–100% 0 1 1 0 1 1 1 0 1
Data presented is number of respondents.evaluating conducting studies this way, and others considering this
change. A number of concerns were raised within the survey, which
will require the drug development industry as a whole to address in
order to increase acceptance and adoption of this reﬁnement. Whilst
most of the respondents were based within Europe and the USA, we re-
ceived an appropriate number of responses from the facilities actively
running these studies (within both CROs and pharmaceutical compa-
nies), and from the companies outsourcing this work to CROs to have
a representative view of the industry at-large.
With the recent decline in R&D productivity (increases in R&D costs
with output of new drugs remaining static, Cook, Brown, Alexander,
March, Morgan, Satterthwaite, & Pangalos, 2014) better and more efﬁ-
cient strategies are urgently required. However, changes to established
ways of working can require careful consideration and validation. Ideal-
ly, a change in drug development processes would result in a reduction
in costs and timelines, whilst improvingdata quality. In reality, although
it is not always possible to improve all three, it is still advantageous to
improve onewhilstmaintaining the others. The challenge for the indus-
try is to identify and apply the beneﬁts of social housing in terms of an-
imal welfare, quality of science, cost and drug development timelines.
As seen in Table 1, there is a wide range of reasons cited for not
implementing social housing during telemetry recordings. These rea-
sons can be generally divided into ‘physical aspects’ (e.g. the size of
pens/cages, or the telemetry equipment available within the facility)
or ‘risk perceptions’ (e.g. the expectation of reduced data quality or
the risk of cross-contamination). Sharing of experiences and demon-
stration of the successful use of socially housed animals in these studies
may help overcome some of the assumed risks. Information within this
manuscript is intended to provide reassurance and potential solutions
to those facilities that are planning to use socially housed animals in
the future. For facilities that have not yet considered social housing, in-
formation within this manuscript may lead to some discussions for in-
terim measures and/or future reﬁnements.
This survey has highlighted an increase in outsourcing of studies
encompassing cardiovascular measurements compared with previous
surveys (Ewart, Gallacher, Gintant, Guillon, Leishman, Levesque,
McMahon, Mylecraine, Sanders, Suter, Wallis, & Valentin, 2012;
Lindgren, Bass, Briscoe, Bruse, Friedrichs, Kallman, Markgraf, Patmore,
& Pugsley, 2008), as organisational changes within the pharmaceutical
industry continue the trend for consolidating work at CROs (Ewart,
Milne, Adkins, Benjamin, Bialecki, Chen, Ericsson, Gardner, Grant,
Lengel, Lindgren, Lowing, Marks, Moors, Oldman, Pietras, Prior,
Punton, Redfern, Salmond, Skinner, Some, Stanton, Swedberg, Finch, &
Valentin, 2013). The survey also shows a preference of pharmaceutical
companies to use socially housed animals in studies involving telemetry
recording. However, the lack of capital investment to support these
changes in-house may be partly responsible for the expansion in
outsourcing. The survey indicated that very fewpharmaceutical compa-
nies run all their safety pharmacology studies in-house, with even fewer
running toxicology studies in-house. Most rely either entirely on CROs
to run these studies, or in combination with in-house work. Therefore,
the increased implementation of social housingmay lie primarilywithin
the CRO sector. However, the views and acceptance of Sponsors (mainly
within the pharmaceutical and biologicals industry) will also be an im-
portant factor, as their requirements will inﬂuence the CROmarket. The
survey indicated a need to improve communication on this topic as
Fig. 5.Housing on recording and non-recording days (Toxicology studies). The number of respondents housing their animals socially or individually, on recording or non-recording days
within a toxicology study. The numbers within the bars gives the actual number of respondents, for ease of reading.
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cial housing options at CROs, whereas comments from CROs indicate
there are few requests for these conditions from Sponsors.
The main barriers to adoption of social housing are discussed below
and are summarised in Tables 4, 5 and 6.Table 4
Potential considerations/recommendations for social housing on safety pharmacology
studies.
Major barriers identiﬁed in the survey and possible resolutions
Limitations of recording equipment currently being used (e.g. signal cross talk)
▪ Advances in technology allows recording from multiple animals in the same
pen/cage
▪ Consider using an unrecorded companion animal if pen/cage size allows
Study design (e.g. Latin-square preferred design may lead to cross-contamination
risks if different animals receive different dose levels within the same pen/cage)
▪ Consider using a partial Latin square design (e.g. two animals receive the same
dose level on each occasion), see Prior, Billing, Wallace, South, Oldman, Moors,
Edmunds, & Milne, 2015
▪ Consider using an ascending dose design
▪ Consider dosing different dose levels within the same pen/cage if test article
characteristics suggest low contamination risk
▪ Consider including minimal drug-exposure sampling to monitor incidence of
cross-contamination
Quality of data obtained
▪ Publications indicate that social housing of animals does not impact the qual-
ity of the data in both dogs and NHPs (e.g., Klumpp, Trautmann, Markert, &
Guth, 2006; Prior, Billing, Wallace, South, Oldman, Moors, Edmunds, & Milne,
2015)
▪ In this survey, the majority of respondents indicated that the data was the
same or better from socially housed animals (8/9 dog, 4/4 minipig and 10/11
NHP respondents) compared to individual housed historical data4.1. Limitations in recording equipment
Social housing is facilitated when using a telemetry system having
independent frequencies for each animal. Although the recent introduc-
tion of new technologies should enable the concept andmethods for so-
cial housing during telemetry recordings to be available to a wider
number of companies, the principles of this have been available to
users of other technologies for some time. Whilst some groups using
these alternative technologies have socially housed during safety phar-
macology (Klumpp, Trautmann, Markert, & Guth, 2006; Markert,
Trautmann, Groß, Ege, Mayer, & Guth, 2012) or toxicology studies
(Ward, 2009), others did not (Prior, McMahon, Schoﬁeld, & Valentin,
2009; Chaves, Zingaro, Yordy, Bustard, O'Sullivan,
Galijatovic-Idrizbegovic, Schuck, Christian, Hoe, & Briscoe, 2007;
Sivarajah, Collins, Sutton, Regan, West, Holbrook, & Edmunds, 2010).
This difference is likely to be due to many of the reasons highlighted
within this survey. Many of the companies surveyed will upgrade to
new equipment in the future that allows for social housing, as the sale
of and/or support for older systems are phased out by the manufac-
turers. Therefore, the most common technical barrier to the adoption
of social housing during recordings will disappear over time.Colony management (e.g. concerns about introducing a new animal if one has to
be removed from the social group)
▪ Ensure close observation and knowledge of individual animals within the
colony
▪ Consider removing ‘unruly/disruptive’ animals from the colony
▪ May have to increase the colony size to allow for more combination options
once on study
Increased/abnormal activity due to the presence of multiple animals in the
pen/cage
▪ Ensure sufﬁcient acclimatisation in the study grouping prior to the start of the
study
▪ Publications indicate that social housing does not detrimentally affect heart
rates in comparison to individual housing (e.g., Kaiser, Tichenor, Regalia, York,
& Holzgrefe, 2015; Klumpp, Trautmann, Markert, & Guth, 2006; Prior, Billing,
Wallace, South, Oldman, Moors, Edmunds, & Milne, 2015)
Validation of processes required for social housing
▪ Consider performing a validation study in socially housed animals so results
can be compared to historical data from individually housed animals
▪ Review statistical power to detect cardiovascular changes in socially housed
animals (using various study designs and animal numbers, if appropriate)4.2. Pen/cage size and room layout
Individual facilities are unique in the way their telemetry recording
rooms and stock colony holding rooms are arranged, and it can be difﬁ-
cult to make major changes to this infrastructure (requiring time and
capital investment) unless there is a speciﬁc reason or desire to do so.
European facilities comply with, or exceed, the updated animal welfare
laws (Directive 2010/63/EU, 2010) so these pens tend to have larger
available areas per animal, which may facilitate social housing during
recordings. Many of these companies have other facilities worldwide
(or exchange studieswithin different countries, somayharmonise prac-
tices), and this may increase the uptake of social housing through staff
exchanges, technical talks, in-house 3Rs awards, etc. The business/ﬁ-
nancial decisions to make these infrastructure changes would be
strengthened by 1) a change in regional directives (e.g. as observed inEurope), 2) scientiﬁc justiﬁcation/acceptance within the industry and
3) Sponsor requests to CROs.
Some facilities hold animals between studies in large groups in sep-
arate rooms, then move animals to individual pens/cages for recording.
Table 5
Potential considerations/recommendations for use of companion animal on safety phar-
macology studies.
Major barriers identiﬁed in the survey and possible resolutions
Cross contamination
▪ Consider the wash out period required for the companion animal (may be
dependent on the characteristics of the test item)
▪ Consider the risk of contamination taking in account known information about
the test material i.e. dose route, route of excretion, dose levels to be used
▪ Consider taking single proof-of-exposure blood samples
Sponsor expectation
▪ Consider providing a data set to Sponsors indicating that the presence of a
companion animal has no impact on the data quality
Fate of undosed animal after study completion
▪ Consider in-house procedures to ensure that the companion animal can be
used as a companion animal on future studies
Impact on costs/increase in size of colony
▪ Consider the source of the companion animal, this may be an animal where
the telemetry equipment is no longer viable, or an animal that has been
rejected from other studies (e.g. from other safety pharmacology or toxicology
studies)
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animals to socialise during periods of non-recording, with suitable
equipment it should also be possible to allow this to continue during
recordings.Table 6
Potential considerations/recommendations for social housing on toxicology studies.
Major barriers identiﬁed in the survey and possible resolutions
Damage to the equipment by pen/cage mates
▪ Consider the amount of acclimatisation to the jackets prior to the study start
and if further acclimatisation/refreshing should be performed before each
recording session during the study
▪ Consider using a second jacket or T-shirt under the outer jacket, to cover the
ECG leads
▪ Consider using implanted technology
▪ Kaiser, Tichenor, Regalia, York, & Holzgrefe (2015) indicates that there was no
increase in incidence of equipment damage in paired NHPs vs single housed
animals
Limitation of the recording equipment currently being used (e.g. signal cross-talk)
▪ Consider using alternative technologies which allow for multiple signals to be
recorded
Quality of data obtained
▪ Publications indicate that social housing does not impact the quality of data in
both dogs and NHPs (e.g. Kaiser, Tichenor, Regalia, York, & Holzgrefe, 2015;
Sadekova, Boudreau, & Norton, 2015; Xing, Lu, Hu, Wang, Zhao, Zheng,
Schoﬁeld, Oldman, Adkins, Yu, Platz, Ren, & Skinner, 2015)
▪ In companies that had experience of social housing 8/9 dog, 3/3 minipig and
8/9 NHP respondents indicated that the data obtained was the same or better
than from individually housed animals
Temperament of individual animals
▪ Consider the acclimatisation period prior to the start of study investigations
▪ Hierarchies/dominance
▪ Age of animals being used
▪ Consider working with the supplier to assess compatibility of animals prior to
arrival
Validation of processes required for social housing
▪ Safety pharmacology studies are publishing data on social housing (Klumpp,
Trautmann, Markert, & Guth, 2006; Prior, Billing, Wallace, South, Oldman,
Moors, Edmunds, & Milne, 2015)
▪ Consider investigating the implications of social housing during the pre--
treatment phase of studies to build up data on processes and impact
Monitoring of clinical signs observed in individual animals
▪ Consider the expected effects of test compound (indications from previous
work e.g. MTD studies)
▪ Consider the use of CCTV cameras and methods of identifying individual ani-
mals (e.g. colour coded jackets)
Size of animals
▪ Consider the age/weight of the animals being used
▪ Consider the introduction procedures utilised when the animals ﬁrst arrive at
the site
▪ Consider the acclimatisation to the social groups prior to the start of any
investigations4.3. Use of a companion animal
If facilities have pens/cages of sufﬁcient size to house two animals
(complying with local laws) but their telemetry equipment is not able
to record from both simultaneously, the inclusion of an unrecorded
companion animal should be considered. One option is for the compan-
ion animal to also be part of the study, but dosed and recorded on a dif-
ferent day. However, this could prolong the study duration due to the
staggered dosing. Alternatively, the companion animal may be an
undosed animal and not included in the study (e.g. part of the stock col-
ony), but instead provided solely for companionship. However, there is
a potential risk of cross-contamination of the companion animal, which
could restrict possible future use of this animal on another study. There
are also concerns that inclusion of a companion animal could increase
the overall number of animals used and potentially the size of stock col-
onies, however, as the companion animal is not undergoing study pro-
cedures (dosing, etc), this is still considered a reﬁnement for the study
animal. Study designs and concerns around abnormal/increased activity
due to the second animal are addressed below.
4.4. Changes in animal behaviour/activity and sensitivity of cardiovascular
data
There is a growing pool of data available comparing cardiovascular
data from socially housed animals with data from individually housed
animals, in both safety pharmacology and toxicology study settings.
Studies showing no signiﬁcant difference in cardiovascular data in so-
cially housed compared with individually housed animals have been
published in dogs (Kearney, Appleby, Kieper, & Atterson, 2016 (this
issue); Prior, Billing, Wallace, South, Oldman, Moors, Edmunds, &
Milne, 2015; Sadekova, Boudreau, & Norton, 2015; Sadekova,
Boudreau, & Norton, 2016 (this issue)) and cynomolgus monkeys
(Kaiser, Tichenor, Regalia, York, & Holzgrefe, 2015; Tichenor, Regalia,
Holzgrefe, Lilly, Wilcox, & Kaiser, 2016 (this issue)). In contrast, other
publications indicate that lower heart rates were obtained in socially
housed cynomolgus monkeys (Bétat, Coquelin, Infanti, Delpy, & Drieu
la Rochelle, 2014; Kreckler, Grosh, Schneider, Niehoff, Foley, & Osinski,
2015; Xing, Lu, Hu, Wang, Zhao, Zheng, Schoﬁeld, Oldman, Adkins, Yu,
Platz, Ren, & Skinner, 2015) and dogs (Klumpp, Trautmann, Markert,
& Guth, 2006; Ward, 2009) compared to individually housed animals.
A change in heart rate for socially housed animals could be interpreted
a number of ways. For instance: an increase could indicate higher stress
levels, or it could be a consequence of more interactions between the
animals and/or more movement in what might be a slightly larger
pen/cage than used for individual animals. A decrease in heart rate
might indicate lower stress in a social setting, or it might indicate ani-
mals have ‘settled’ quicker after disturbances as they have a companion
to buffer stress (Sanchez,McCormack, &Howell, 2015; Ruis, de Groot, te
Brake, Dinand Ekkel, van de Burgwal, Erkens, Engel, Buist, Blokhuis, &
Koolhaas, 2001b). It will be important for those implementing social
housing to understand and interpret the effects of social housing on car-
diovascular data in their own facilities.
4.5. Study design
The standard study design for safety pharmacology studies is the
Latin-square cross-over design (Guth, Chiang, Doyle, Engwall, Guillon,
Hoffmann, Koerner, Mittelstadt, Ottinger, Pierson, Pugsley, Rossman,
Walisser, & Sarazan, 2015), which is widely accepted as conferring the
best statistical power (sensitivity to detect changes in cardiovascular
parameters of interest; Aylott, Bate, Collins, Jarvis, & Saul, 2011;
Leishman, Beck, Dybdal, Gallacher, Guth, Holbrook, Roche, & Wallis,
2012). Some facilities performing studies with socially housed animals
have retained the Latin-square design, whereby each animal within
the pen receives a different dose level, with no reports of cross-
contamination in over 15 years of using this approach, based on drug
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nication). Other facilities have adopted a slightly more conservative ap-
proach, whereby a ‘partial’ Latin-square is used, such that the two
animals within the pen receive the same dose level (Prior, Billing,
Wallace, South, Oldman, Moors, Edmunds, & Milne, 2015) and report
similar sensitivity to previous Latin-square designs. Alternatively, an as-
cending dose design, whereby all the animals within the pen/cage re-
ceive the same dose level may be an even more conservative option,
and this design can exhibit similar statistical power (Ewart, Milne,
Adkins, Benjamin, Bialecki, Chen, Ericsson, Gardner, Grant, Lengel,
Lindgren, Lowing, Marks, Moors, Oldman, Pietras, Prior, Punton,
Redfern, Salmond, Skinner, Some, Stanton, Swedberg, Finch, &
Valentin, 2013; Prior, Billing, Wallace, South, Oldman, Moors,
Edmunds, & Milne, 2015; Guth, Bass, Briscoe, Chivers, Markert, Siegl, &
Valentin, 2009) to Latin-square designs, although may be confounded
by day effects. The adoption of a Latin-square study design may be de-
pendent on the knownproperties of the compound, the dose levels cho-
sen, and the species. For example, it is known that dogs in the laboratory
may ingest vomit and/or faeces from pen/cagemates and cynomolgus
monkeys spend substantial time grooming/licking pen/cagemates. If
the chosen dose level is not expected to cause emesis (e.g. a well-
characterised compound, or a test compound where the maximum tol-
erated dose (MTD) is known) then the risk of cross-contamination may
be considered low. Inclusion of minimal blood sampling for conﬁrma-
tion of drug-exposure may be useful to identify any deviations due to
cross-contamination within socially housed animals and publications
exploring the incidence of cross-contamination using these study de-
signs would be valuable. As study sensitivity and test article-
characteristics are unique to each facility, the study design for socially
housed safety pharmacology studies needs to be assessed within the
validation studies and on a study-by-study basis.4.6. Food consumption/clinical signs monitoring
The measurement of food consumption from individual animals is
not a requirement within safety pharmacology studies, however it is
often recorded as a measure of general clinical condition of the animal.
Depending on the time of day food is offered, and the timing in relation
to any critical periods of cardiovascular monitoring, animals could be
separated for a short period of time (e.g. 1 h) to allow these data to be
obtained, and some facilities are using this approach (this was the deﬁ-
nition for partial social housing within the survey). Other facilities sim-
ply provide each animal with a separate food allowance and make
careful observations on the consumption.
Collection of food consumption data is often a requirement for toxi-
cology studies; however, as animals are generally socially housed on
other days within the study, the cardiovascular recording should not
impact these data if the same procedures are followed. Efforts should
be made, however, to reduce the disturbance to the animals these pro-
cedures may cause on the cardiovascular recording days. Whole group
or cage assessments for food consumption are acceptable within toxi-
cology studies, particularly for NHPs. Automated systemsmay be imple-
mented on these types of studies to measure food consumption from
socially housed non-rodents, similar to those already available for ro-
dents (Krohn, Farlov, & Hansen, 2011) or to those usedwithin academia
(Wilson, Fisher, Fischer, Lee, Harris, & Bartness, 2008) or more sophisti-
cated systems used in pig production facilities e.g. Young & Lawrence
(1994).
Clinical signs can be monitored in safety pharmacology and toxicol-
ogy studies via closed circuit television cameras (CCTV), but amethod of
individual identiﬁcation may be required in socially housed animals.
Animals could bemarked non-invasively on theﬂankor the head, or dif-
ferent colour jackets could be worn (e.g., see Rose, de Heer, Korte, van
der Harst, Weinbauer, & Spruijt, 2012). Clinical signs are typically mon-
itored on non-recording days from socially housed animals ontoxicology studies, thus if the same processes are adopted, then it
should also be possible on the telemetry recording days.
4.7. Damage to equipment (jacketed telemetry)
Jacketed telemetry has been used within the industry for over a de-
cade (Hunter, Schoﬁeld, Gracie, Moors, Philp, Carter, Prior, Valentin, &
Hammond, 2004) and has allowed the integration of quality continuous
cardiovascular assessments into toxicology studies. However, imple-
mentation of jacketed telemetry into socially housed conditions could
present some issues. Even single housed animals are able to tamper
with their jackets and damage/destroy the ECG leads, leading to loss
of data (Chui, Fosdick, Conner, Jiang, Bruenner, & Vargas, 2009) and so-
cially housed animals may increase the incidence of this, due to interac-
tions with equipment of pen/cagemates. However, comments within
the survey from companies implementing (or validating) social housing
suggest that the animals are less prone to jacket destruction, perhaps as
they are sufﬁciently ‘enriched’ by their companion(s) (Kaiser, Tichenor,
Regalia, York, & Holzgrefe, 2015; Sadekova, Boudreau, & Norton, 2015;
Xing, Lu, Hu, Wang, Zhao, Zheng, Schoﬁeld, Oldman, Adkins, Yu, Platz,
Ren, & Skinner, 2015). The keys to successful jacketed telemetry are
(whether animals are singly or socially housed) appropriate jacket de-
sign, size and placement, along with sufﬁcient acclimatisation to the
jackets, as these will reduce the risk of damage of the jackets during
the study. There are a number of articles with thorough descriptions
of acclimatisation regimens (Derakhchan, Chui, Stevens, Gu, & Vargas,
2014; Prior, McMahon, Schoﬁeld, & Valentin, 2009; APV Scientiﬁc Advi-
sory Committee Guidelines). Some ‘tips’ and solutions for successful re-
cordings include introducing animals to wearing jackets from a young
age (e.g., at the breeders facility), wearing an undershirt or bandaging
or another jacket below the outer jacket (Ascah, Abtout, Pouliet,
Bassett, & Authier, 2015; Chui, Fosdick, Conner, Jiang, Bruenner, &
Vargas, 2009; Ward, Milliken, Patel, & McMahon, 2012; Xing, Lu, Hu,
Wang, Zhao, Zheng, Schoﬁeld, Oldman, Adkins, Yu, Platz, Ren, &
Skinner, 2015) to protect the electrodes, modifying the jackets to hide
zips (Xing, Lu, Hu, Wang, Zhao, Zheng, Schoﬁeld, Oldman, Adkins, Yu,
Platz, Ren, & Skinner, 2015). Additional acclimatisation sessions to
jackets before each recording session (particularly important for longer
studies where there may be a gap of a number of weeks between re-
cording sessions) could also be used. Additionally, some practices may
be transferrable from ambulatory infusion toxicology studies which
are frequently run in social housed conditions.
4.7.1. Other 3Rs' opportunities highlighted within the survey results
Although the survey was primarily interested in practices and views
on social housing during telemetry recordings, a number of answers
highlighted some interesting opportunities for additional animal wel-
fare improvements. These are discussed below.
4.8. Number of animals used (Reduction)
Most companies use four animals in their safety pharmacology te-
lemetry studies, usually of the same sex. However, some companies
use six or eight animals and amix of both sexes. The number of animals
used should depend on the study sensitivity required for a given study
type at each speciﬁc facility, however, a geographical trend indicated
European companies often use fewer animals.Whilst the use of four an-
imals can deliver acceptable test sensitivity for themajority of themea-
sured parameters, there can be small improvements in test sensitivity
when increasing to eight animals (Chiang, Bass, Cooper, Engwall,
Menton, & Thomas, 2007; Sivarajah, Collins, Sutton, Regan, West,
Holbrook, & Edmunds, 2010; Guth, Bass, Briscoe, Chivers, Markert,
Siegl, & Valentin, 2009). If social housing leads to less variability within
the data, there could be opportunities for facilities to reduce the number
of animals used, dependent on study requirements. Reducing the
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and timelines (technician time, data processing time, etc.).
4.9. Housing practices during acclimatisation/non-recording days
(Reﬁnement)
The survey highlighted that in 100% of respondent facilities, NHPs are
socially housed as stock or on non-recording days. However, dogs are still
housed individually in a small proportion of facilities, even as stock or on
non-recording days in safety pharmacology studies or for the entirety of
toxicology studies. This may be due to infrastructure reasons or concerns
around compatibility/conﬂict within groups. For guidance on successful
social housing, please refer to NC3Rs, 2006 and Prescott, Morton,
Anderson, Buckwell, Heath, Hubrecht, Jennings, Robb, Ruane, Swallow,
& Thompson, 2004. Some respondents expressed concerns about chang-
ing the housing conditions within a study, preferring tomaintain the an-
imals in a stable condition at all times rather than switching the animals
between social and single housing on recording and non-recording days,
respectively. These comments provide support for social housing
throughout the study. As most facilities are now social housing NHPs
on non-recording days, this should increase the adoption of social hous-
ing on recording days where technically feasible. There is also the poten-
tial for this practice to extend to the other non-rodent species.
4.10. Use of minipigs
An unexpectedly high number of respondents run safety pharmacol-
ogy and toxicology telemetry studies in the minipig (20 and 13 compa-
nies, respectively). When the dog is considered unsuitable as the non-
rodent for use, the minipig is often the second species of choice and
can potentially be a suitable model for many different toxicology
study types (Bode, Clausing, Gervais, Loegsted, Luft, Nogues, & Sims,
2010). The acceptable cardiovascular data from these animals
(Authier, Gervais, Fournier, Gauvin, Maghezzi, & Troncy, 2011;
Markert, Stubhan, Mayer, Trautmann, Klumpp, Schuler-Metz,
Schumacher, & Guth, 2009) and the stability of pairings means that
minipigs can be considered as a suitable non-rodent species for teleme-
try studies in socially-housed conditions.Fig. 6. Flow-diagram with decision tree for grou4.11. Conclusions and recommendations
The implementation of social housing during telemetry recordings
in safety pharmacology and toxicology studies is an achievable goal.
However, individual companies will have varying challenges according
to their current practice and infrastructure, whichwill be unique to each
speciﬁc facility. For example, changing to social housingmay require re-
view/modiﬁcation of physical aspects such as pen/cage sizes, room
availability and telemetry hardware, and/or process aspects such as ac-
climatisation of animals to each other and to recording areas, stock col-
ony/pair compositions and study designs. Each facility will need to
investigate the optimal conditions to ensure the cardiovascular data ob-
tained from socially housed animals is of similar, or better, quality and
sensitivity than from individually housed animals. If Sponsors do not
wish to invest in their in-house facilities, then the trends identiﬁed in
the survey shows increased opportunities to use CROs for socially
housed studies. CROs need to meet market expectations but concerns
over possible decreases in capacity/number of studies that can be of-
fered when using social housing will need to be addressed. CROs may
therefore retain capabilities to run studies according to all possible re-
quests as an interim measure. Further demonstration of cost or time-
efﬁciencies, in addition to an increased data quality, will accelerate the
implementation of socially housed studies.
The implementation of social housing during telemetry recording
may be most straightforward for standard studies initially, e.g. oral dos-
ing studies when using cautious dose levels (to minimise emesis and
cross-contamination) if theMTD is already known. Theremay be specif-
ic studies where, in order to ensure the likelihood of successful comple-
tion, animals will need to be singly housed (e.g., if using a technical
dosing route or a speciﬁc compound which may cause aggressiveness
or other clinical signs which may affect the welfare of pen/cage
mates). However, the overall intention should be to consider social
housing as normal/default from the start, and ensure robust scientiﬁc
rationale is used to deviate from this. Fig. 6 shows a ﬂow diagram
with decision points and suggestions for housing options for individual
studies. Additionally, pair housing of animalsmay bemore achievable in
the short term for some companies than housing and recording from
larger groups of animals.p-housing on safety pharmacology studies.
86 H. Prior et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 75–87In conclusion, although the majority of the industry does not yet
have the experience or capabilities for recording from socially housed
animals in safety pharmacology and toxicology studies, there is support
to implement this reﬁnement. Continued discussions, sharing of best
practice and data from companies already socially housing, combined
with technology improvements and investments in infrastructure are
required to maintain the forward momentum of this reﬁnement across
the industry.
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